1212 related articles for article (PubMed ID: 29207310)
1. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.
Tokunaga R; Zhang W; Naseem M; Puccini A; Berger MD; Soni S; McSkane M; Baba H; Lenz HJ
Cancer Treat Rev; 2018 Feb; 63():40-47. PubMed ID: 29207310
[TBL] [Abstract][Full Text] [Related]
2. Wrinkle in the plan: miR-34a-5p impacts chemokine signaling by modulating CXCL10/CXCL11/CXCR3-axis in CD4
Hart M; Nickl L; Walch-Rueckheim B; Krammes L; Rheinheimer S; Diener C; Taenzer T; Kehl T; Sester M; Lenhof HP; Keller A; Meese E
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33229509
[TBL] [Abstract][Full Text] [Related]
3. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond.
Karin N
Front Immunol; 2020; 11():976. PubMed ID: 32547545
[TBL] [Abstract][Full Text] [Related]
4. Review: The chemokine receptor CXCR3 and its ligands CXCL9, CXCL10 and CXCL11 in neuroimmunity--a tale of conflict and conundrum.
Müller M; Carter S; Hofer MJ; Campbell IL
Neuropathol Appl Neurobiol; 2010 Aug; 36(5):368-87. PubMed ID: 20487305
[TBL] [Abstract][Full Text] [Related]
5. Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.
Dengel LT; Norrod AG; Gregory BL; Clancy-Thompson E; Burdick MD; Strieter RM; Slingluff CL; Mullins DW
J Immunother; 2010; 33(9):965-74. PubMed ID: 20948440
[TBL] [Abstract][Full Text] [Related]
6. Regulation of CXCL9/10/11 in oral keratinocytes and fibroblasts.
Ohta K; Shigeishi H; Taki M; Nishi H; Higashikawa K; Takechi M; Kamata N
J Dent Res; 2008 Dec; 87(12):1160-5. PubMed ID: 19029086
[TBL] [Abstract][Full Text] [Related]
7. Targeting CXCL9/10/11-CXCR3 axis: an important component of tumor-promoting and antitumor immunity.
Pan M; Wei X; Xiang X; Liu Y; Zhou Q; Yang W
Clin Transl Oncol; 2023 Aug; 25(8):2306-2320. PubMed ID: 37076663
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis.
Basset L; Chevalier S; Danger Y; Arshad MI; Piquet-Pellorce C; Gascan H; Samson M
J Mol Med (Berl); 2015 Dec; 93(12):1355-67. PubMed ID: 26199110
[TBL] [Abstract][Full Text] [Related]
9. Dual specificity of anti-CXCL10-CXCL9 antibodies is governed by structural mimicry.
Fagète S; Rousseau F; Magistrelli G; Gueneau F; Ravn U; Kosco-Vilbois MH; Fischer N
J Biol Chem; 2012 Jan; 287(2):1458-67. PubMed ID: 22041899
[TBL] [Abstract][Full Text] [Related]
10. An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4.
Lasagni L; Francalanci M; Annunziato F; Lazzeri E; Giannini S; Cosmi L; Sagrinati C; Mazzinghi B; Orlando C; Maggi E; Marra F; Romagnani S; Serio M; Romagnani P
J Exp Med; 2003 Jun; 197(11):1537-49. PubMed ID: 12782716
[TBL] [Abstract][Full Text] [Related]
11. Modelling of the membrane receptor CXCR3 and its complexes with CXCL9, CXCL10 and CXCL11 chemokines: putative target for new drug design.
Trotta T; Costantini S; Colonna G
Mol Immunol; 2009 Dec; 47(2-3):332-9. PubMed ID: 19800124
[TBL] [Abstract][Full Text] [Related]
12. Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors.
Bronger H; Magdolen V; Goettig P; Dreyer T
Cancer Metastasis Rev; 2019 Sep; 38(3):417-430. PubMed ID: 31482487
[TBL] [Abstract][Full Text] [Related]
13. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function.
Colvin RA; Campanella GS; Sun J; Luster AD
J Biol Chem; 2004 Jul; 279(29):30219-27. PubMed ID: 15150261
[TBL] [Abstract][Full Text] [Related]
14. Bu-Shen-Fang-Chuan formula attenuates T-lymphocytes recruitment in the lung of rats with COPD through suppressing CXCL9/CXCL10/CXCL11-CXCR3 axis.
Li Q; Sun J; Cao Y; Liu B; Li L; Mohammadtursun N; Zhang H; Dong J; Wu J
Biomed Pharmacother; 2020 Mar; 123():109735. PubMed ID: 31864210
[TBL] [Abstract][Full Text] [Related]
15. CXCL9, CXCL10, CXCL11, and their receptor (CXCR3) in neuroinflammation and neurodegeneration.
Koper OM; Kamińska J; Sawicki K; Kemona H
Adv Clin Exp Med; 2018 Jun; 27(6):849-856. PubMed ID: 29893515
[TBL] [Abstract][Full Text] [Related]
16. CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid.
Manousou P; Kolios G; Drygiannakis I; Koulentaki M; Pyrovolaki K; Voumvouraki A; Notas G; Bourikas L; Papadaki HA; Kouroumalis E
Clin Exp Immunol; 2013 Apr; 172(1):9-15. PubMed ID: 23480180
[TBL] [Abstract][Full Text] [Related]
17. Computational Study of C-X-C Chemokine Receptor (CXCR)3 Binding with Its Natural Agonists Chemokine (C-X-C Motif) Ligand (CXCL)9, 10 and 11 and with Synthetic Antagonists: Insights of Receptor Activation towards Drug Design for Vitiligo.
Aguilera-Durán G; Romo-Mancillas A
Molecules; 2020 Sep; 25(19):. PubMed ID: 32992956
[TBL] [Abstract][Full Text] [Related]
18. Effect of JAK Inhibitors on Release of CXCL9, CXCL10 and CXCL11 from Human Airway Epithelial Cells.
Fenwick PS; Macedo P; Kilty IC; Barnes PJ; Donnelly LE
PLoS One; 2015; 10(6):e0128757. PubMed ID: 26090665
[TBL] [Abstract][Full Text] [Related]
19. CXCR3 ligands are associated with the continuum of diffuse alveolar damage to chronic lung allograft dysfunction.
Shino MY; Weigt SS; Li N; Palchevskiy V; Derhovanessian A; Saggar R; Sayah DM; Gregson AL; Fishbein MC; Ardehali A; Ross DJ; Lynch JP; Elashoff RM; Belperio JA
Am J Respir Crit Care Med; 2013 Nov; 188(9):1117-25. PubMed ID: 24063316
[TBL] [Abstract][Full Text] [Related]
20. Desiccating stress-induced chemokine expression in the epithelium is dependent on upregulation of NKG2D/RAE-1 and release of IFN-γ in experimental dry eye.
Coursey TG; Bohat R; Barbosa FL; Pflugfelder SC; de Paiva CS
J Immunol; 2014 Nov; 193(10):5264-72. PubMed ID: 25288568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
